VOL. XVIII, 1969

140

RB
147
M48

METABOLISM
Clinical and Experimental

CONTENTS

No. 1 (January)

SERUM CREATINE PHOSPHOKINASE IN MUSCULAR DYSTROPHY DURING IODINATED AMINO ACID THERAPY
T. S. Danowski, S. P. Balcerzak, G. Sabeh and J. W. Vester 1

ROLE OF GASTRO-INTESTINAL FACTORS IN REACTIVE HYPOGLYCEMIA
Egils Veverbrants, Ward Olsen and Ronald A. Arky 6

EFFECTS OF PROLONGED STARVATION ON BLOOD LIPID LEVELS OF OBESE SUBJECTS . . . . . *Ivor M.D. Jackson* 13

TURNOVER RATE OF PLASMA FFA AND RATE OF ESTERIFICATION OF PLASMA FFA TO PLASMA TRIGLYCERIDES IN OBESE HUMANS BEFORE AND AFTER WEIGHT REDUCTION . . . *J. C. Birkenhäger and T. Tjabbes* 18

POTASSIUM IN BONE: EVIDENCE FOR A NONEXCHANGEABLE FRACTION
James M. Hartsuck, James E. Johnson and Francis D. Moore 33

DISTORTIONS OF NORMAL BONE CELL METABOLISM INDUCED IN MULTIPLE MYELOMA . . . . . *George Nicholas, Jr., and Phin Cohen* 38

TYPE III HYPERLIPOPROTEINEMIA WITH LOW PLASMA THYROXINE BINDING GLOBULIN . . . . . *Jørn Dyerberg* 50

THYROIDAL SUPPRESSIBILITY AFTER STOPPING LONG-TERM TREATMENT OF THYROTOXICOSIS WITH ANTI-THYROID DRUGS
W. D. Alexander, R. McG. Harden, D. McLarty and J. Shimmins 58

COMPARISON OF URINARY PHOSPHATE, URATE AND MAGNESIUM EXCRETION FOLLOWING PARATHYROID HORMONE ADMINISTRATION TO NORMAL MAN . . *Weldon D. Shelp, Thomas H. Steele and Richard E. Rieselbach* 63

IN VITRO INSULINOGENIC EFFECT OF MATERIAL HARVESTED FROM INCUBATED GUT LOOPS OF RATS
John G. Haddad, Jr., and John A. Owen, Jr. 71

SERUM LIPID RESPONSES TO ETHYL-P-CHLOROPHENOXYISOBUTYRATE WITH DIFFERENT DIETARY FATS
Mohan G. Kokatnur, Gray T. Malcom and Robert D. Martinez 73

No. 2 (February)

THE SARCOPLASMIC RETICULUM IN THYROTOXIC HYPOXALEMIC PERIODIC PARALYSIS ..... *H. S. Schutta and J. L. Armitage* 81
EFFECT OF ARGININE ON INSULIN RELEASE IN VITRO ..... *P. Edgar, D. Rabinowitz, T. J. Merimee and E. Almogela* 84
EFFECT OF INGESTED MANNOHEPTULOSE IN ANIMALS AND MAN *Josef K. Viktora, Brian F. Johnson, Juan C. Penhos, Charles A. Rosenberg and Frederick W. Wolff* 87
HYPERGLYCEMIC, NONKETOTIC COMA IN THE PATIENT WITH BURNS: FACTORS IN PATHOGENESIS ..... *David D. Oakes, Paul H. Schreibman, Richard S. Hoffman and Ronald A. Arky* 103
METABOLIC HOMEOSTASIS IN JUVENILE DIABETES MELLITUS. I. ROLE OF GROWTH HORMONE ..... *Lester Baker, Allen W. Root, Nasir Haque and Robert Kaye* 110
RATE OF REMOVAL OF COLLAGEN AND MINERAL FROM BONE AND CARTILAGE ..... *H. E. Firschein and Nancy W. Alcock* 115
THE EFFECT OF FEEDING FREQUENCY ON DIURNAL PLASMA FREE FATTY ACIDS AND GLUCOSE LEVELS ..... *Walter M. Bortz, Paula Howat and William L. Holmes* 120
ORAL CALCIUM ABSORPTION IN PATIENTS WITH RENAL FAILURE TREATED BY CHRONIC HEMODIALYSIS ..... *Saul M. Genuth, Victor Vertes and Jack R. Leonards* 124
COMPARATIVE EFFECTS OF THYROTROPIN AND LONG-ACTING THYROID STIMULATOR ON THYROIDAL INTERMEDIARY METABOLISM: RELATIONSHIP TO PYRIDINE NUCLEOTIDE LEVELS ..... *Gerald Burke* 132
EFFECT OF CLOFIBRATE ON SERUM THYROXINE TRANSPORT AND FREE THYROXINE LEVELS ..... *Jose Barbosa and Leo Oliner* 141
EFFECT OF PHENFORMIN IN NONDIABETIC HUMANS. ESTIMATION OF GLUCOSE TURNOVER RATE AND CORI CYCLE ACTIVITY *G. L. Searle, R. Gulli and R. R. Cavalieri* 148
EFFECTS OF STARVATION ON INSULIN AND GLUCOSE RELEASE FROM ISOLATED ISLETS OF LANGERHANS OF THE RAT *Keith D. Buchanan, James E. Vance and Robert H. Williams* 155
EFFECTS OF VARIOUS ROUTES OF CAFFEINE ADMINISTRATION ON ORAL AND INTRAVENOUS GLUCOSE TOLERANCE TESTS IN DOGS *Oscar A. P. DeCastro, Herschel Sandberg, Leonard J. Feinberg and Samuel Bellet* 163
PRODUCTION OF INSULIN A AND B CHAINS BY ISOLATED RAT ISLETS *John M. Zahradnik, Joseph C. Meek and Robert E. Bolinger* 172

No. 3 (March)

EXPERIENCE WITH A RAPID ORAL METYRAPONE TEST AND THE PLASMA ACTH CONTENT IN DETERMINING THE CAUSE OF CUSHING'S SYNDROME ..... *Lowell L. Sparks, Renata P. Smilo, Fotios Ch. Pavlatos and Peter H. Forsham* 175

KETOSIS, WEIGHT LOSS, URIC ACID, AND NITROGEN BALANCE IN OBESE WOMEN FED SINGLE NUTRIENTS AT LOW CALORIC LEVELS
Janet Dale Bell, Sheldon Margen and Doris Howes Calloway 193
RATE OF DRUG METABOLISM IN OBESE VOLUNTEERS BEFORE AND DURING STARVATION AND IN AZOTEMIC PATIENTS . . . *Marcus M. Reidenberg, Harry Kostenbauder and Wallace P. Adams* 209
EFFECTS OF PYRAZINAMIDE ON CARBOHYDRATE AND FAT METABOLISM
W. E. Dulin and G. C. Gerritsen 214
EFFECT OF ADRENERGIC RECEPTOR BLOCKADE ON NICOTINIC ACID-INDUCED PLASMA FFA REBOUND . . . . . *William G. Blackard and Sylvia A. Heidingsfelder* 226
MEASUREMENTS OF IMMUNOLOGICALLY REACTIVE FOLLICLE STIMULATING HORMONE IN SERUM OF NORMAL MALE CHILDREN AND ADULTS
S. Raiti, A. Johanson, C. Light, C. J. Migeon and R. M. Blizzard 234
PLASMA GLUCOSE RESPONSE TO NATURAL VASOPRESSIN IN MATURITY ONSET DIABETICS AND ADULT NONDIABETICS
B. V. Suryanarayana and John R. Kent 241
EARLY INSULIN RESPONSE TO INTRAVENOUS GLUCOSE IN STEROID-STRESS DIABETES . . . . . *Ralph W. Alexander, Peter H. Forsham and Gerold M. Grodsky* 248
SECONDARY PROXIMAL TUBULAR ACIDOSIS . . . . . *Daniel H. Gregory, Frederic E. Walker, Jr., and Alfred Eichenholz* 252

No. 4 (April)

EFFECT OF GLUCAGON ON CONCENTRATION OF SEVERAL FREE AMINO ACIDS IN PLASMA . . . . . *Richard L. Landau and Kathleen Lugibihl* 265
FACTORS AFFECTING ALTERNATE PATHWAYS OF CORTICOSTEROID EXCRETION: POSSIBLE CATABOLITE REPRESSION PHENOMENA IN MAN
Habeeb Bacchus 277
EFFECT OF COFFEE INGESTION ON CATECHOLAMINE RELEASE
Samuel Bellet, Laurian Roman, Oscar DeCastro, Kwan Eun Kim and Alfred Kershbaum 288
ACTION OF HYDRALAZINE ON GLUCOSE TURNOVER AND PLASMA LIPIDS IN DOGS . . . . . *Shafeek S. Sanbar and Silvia A. D. de Romero* 292
MECHANISM OF PLASMA LIPID INCREASES FOLLOWING BRAIN STIMULATION
William H. Gutstein, Daniel J. Schneck and Harold Appleton 300
EFFECTS OF ADRENALECTOMY ON THYROID FUNCTION IN STARVED RATS
Warner H. Florsheim, Raymond T. Mirise, Marjorie A. Faircloth and Albert D. Williams 311
EFFECTS OF PRECEDING DIET AND FASTING ON GLUCOSE TURNOVER IN NORMAL DOGS . . . . . *J. S. Cowan, M. Vranic and G. A. Wrenshall* 319
EFFECT OF ADENINE NUCLEOTIDES ON THYROID HORMONE RELEASE IN VIVO AND IN VITRO . . . . . *Yukio Ochi and Leslie J. DeGroot* 331
EFFECT OF COLD ON PLASMA PROTEIN-THYROXINE INTERACTION IN THE GUINEA PIG . . *Takashi Yamada, Hitoshi Fukuda, Yoshihiro Takemura and Kojiro Shichijo* 339

No. 5 (May)

Effect of Phosphate Supplementation During Immobilization of Normal Men . . . . *Ralph S. Goldsmith, Paul Killian, Sidney H. Ingbar and David E. Bass* 349

The Paradoxical Dexamethasone Response Phenomenon *Leslie I. Rose, Gordon H. Williams, Paul I. Jagger, David P. Lauler and George W. Thorn* 369

Assessment of Pituitary Reserve in Subjects Pretreated with Dexamethasone . . . . . *Arnold M. Moses and Myron Miller* 376

Lack of Dialyzable Insulin Antagonist in Uremia *Mayer B. Davidson, Edmund G. Lowrie and Constantine L. Hampers* 387

Isotopic Determination of Intestinal Calcium Absorption in Normal Subjects . . . . . *Carlos A. Mautalen, Mariana L. Cabrejas and Roberto J. Soto* 395

Palmitate Transport Across Perfused Human Placenta *Andrew J. Szabo, Richard D. Grimaldi and William F. Jung* 406

Comparative Utilization of Glycine-N^{15} Administered Orally or Parenterally . . . . . *O. H. Gaebler and H. C. Choitz* 416

Chronic Effects of Mannoheptulose in Hyperglycemic-Obese Mice *Mitsuru Hoshi and Walton W. Shreeve* 422

Effects of Cystine, Niacin and Taurine on Cholesterol and Bile Acid Metabolism in Rabbits . . . . *Moore J. Burns and Karl S. Self* 427

Function of the Pancreatic B-Cells in Hamsters Bearing a Transplantable Islet Cell Tumor *Jean-Claude Sodoyez, Françoise Sodoyez-Goffaux, Ronald M. Rossen and Piero P. Foa* 433

Response of Serum Mg and K to Glucose and Insulin Infusion in Uremic Dogs . . . . *R. Whang, R. Reyes, D. Rodgers and M. Bryant* 439

No. 6 (June)

Pheochromocytoma: Observations on Mechanism of Carbohydrate Intolerance and Abnormalities Associated with Development of Goldblatt Kidney Following Removal of Tumor *Marion H. Brooks, Atin Guha, Elliot Danforth, Jr., Jacob J. Weinstein and Kevin G. Barry* 445

Serum Insulin and Growth Hormone in Lipoatrophic Diabetes *Naguib A. Samaan and James W. Craig* 460

Active Acromegaly with Anterior Pituitary Failure *Alan L. Plummer, Raymond V. Randall and B. Lawrence Riggs* 469

Evaluation of Three Acute Tests of Hypothalamic-Pituitary Adrenal Function *B. J. Carroll, Margaret J. Pearson and F. I. R. Martin* 476

Effect of Physical Exercise on Adrenocortical Excretion *Samuel Bellet, Laurian Roman and Frank Barham* 484

Sporadic Cretinism and Juvenile Hypothyroidism
M. M. S. Ahuja, I. J. Chopra and C. B. Sridhar 488
Metabolic Response to Simultaneous Infusion of Epinephrine and Propranolol in Obese Adolescents . . . . . *Adalberto Parra and Robert B. Schultz* 497
Effect of Diet on Body Composition Changes After Experimental Injury in Rats . . . *Helena Gilder, Victor DeLeon, Dora Sternberg and Mira Valcic* 509
Effect of Allopurinol on Urinary Ammonia Excretion in Patients with Gout . . . . . *William Ralph Vogler and J. Wanzer Drane* 519

No. 7 (July)

Lipoatrophic Diabetes: An Improved Procedure for the Isolation and Purification of a Diabetogenic Polypeptide from Urine
Lawrence H. Louis 545
A Urinary Diabetogenic Peptide in Proteinuric Diabetic Patients
Lawrence H. Louis and Jerome W. Conn 556
Changes in Body Composition Produced by Prolonged Total Starvation and Refeeding . . . . . *D. L. Barnard, J. Ford, E. S. Garnett, R. J. Mardell and A. E. Whyman* 564
Turnover and Oxidation of Plasma Glucose in Lean and Obese Humans . . . . . *Pavle Paul and Walter M Bortz* 570
Starvation and Anabolic Steroids . . . . . *Vladimir Krizek, Pavel Stepanek and Ludvik Sadilek* 585
Human Chorionic Somato-Mammotropine (HCSM): Lipolytic Action of a Pure Preparation on Isolated Fat Cells
A. R. Genazzani, M. Benuzzi-Badoni and J. P. Felber 593
Effect of Acetylsalicylic Acid and Phenylbutazone on Glucose Absorption in Vitro . . . . . *Samira Saleh, M. T. Khayyal, A. M. El Masri and A. M. Ghazal* 599
Fluctuations of Human Growth Hormone Secretion During Menstrual Cycle: Response to Arginine . . . . . *Thomas J. Merimee, S. Edwin Fineberg and John E. Tyson* 606
Studies on Adrenal Cortical Function in Patients with Lung Cancer . . . . . *Atsuo Kawai, Masao Tamura, Shinichi Tanimoto, Hiomi Honma and Nobusada Kuzuya* 609
Effect of Sodium Salicylate on Induced Lipolysis in Isolated Fat Cells of the Rat . . . . . *Daniel B. Stone, Joseph D. Brown and Ann A. Steele* 620
Influence of Zinc and Vitamin D on Bone Constituents of the Rat . . . . . *I-chia Hsu Chang, Inez Harrill and Elizabeth Dyar Gifford* 625

No. 8 (August)

Editorial: Metabolic Basis of Human Atherosclerosis
Peter T. Kuo 631

Vascular Symptomatic Relief During Administration of Ethylchlorophenoxyisobutyrate (Clofibrate)
Monroe Albert and Marion J. Stansell 635

Tumors Sterols . . . . . *Edwin A. Day, Gray T. Malcom and Myrton F. Beeler* 646

Absorbability of β-Sitosterol in Humans
R. Gordon Gould, Richard J. Jones, George V. LeRoy, Robert W. Wissler and C. Bruce Taylor 652

Radiopotassium Equilibrium in Total Body Potassium: Studies Using ^{43}K and ^{42}K . . . . . *James E. Johnson, James M. Hartsuck, Robert M. Zollinger, Jr., and Francis D. Moore* 663

Renal Clearance of Amylase During Pancreatitis
Robert Mulhausen, David C. Brown and Gerald Onstad 669

Impairment of Biliary Transport as a Cause of Sulfobromophthlein Retention in Fasting Men . . . . . *Edwin M. Bradley, Henry M. Bellamy, Kermit B. Knudsen and Frank R. Lecocq* 675

Use of Respiration Pattern Analysis for Study of Serine Metabolism in Vivo . . . . . *A. L. Kretchmar and E. J. Price* 684

Glycylproline Peptiduria in Familial Hyperostosis of Obscure Nature . . . . . *Michael H. Alderman, George W. Frimpter, Marian Isaacs and Ellen Scheiner* 692

Aldosterone and Sodium Excretion in Obese Subjects on Water Diet . . . . . *R. Smith, E. J. Ross and P. Marshall-Jones* 700

Utility of Expressing Serum Sodium per Unit of Water in Assessing Hyponatremia . . . . . *William H. Waugh* 706

Urinary Amino Acids in Storage Disorders: Mucopolysaccharidosis, Gaucher's Disease and Metachromatic Leucodystrophy
Björn Hultberg, Per-Arne Öckerman and Örjan Eriksson 713

The Cell Membrane: A Common Site of Action of Thyrotropin (TSH) and Long-acting Thyroid Stimulator (LATS)
Gerald Burke 720

No. 9 (September)

Insulin Patterns Prior to and After Onset of Diabetes
T. S. Danowski, Y. B. Lombardo, L. V. Mendelsohn, D. G. Corredor, C. R. Morgan and G. Sabeh 731

Growth Hormone and Insulin Levels in Newly Discovered Glucose Intolerance . . . . . *G. Sabeh, D. G. Corredor, L. V. Mendelsohn, C. R. Morgan, J. C. Sieracki, J. H. Sunder, J. P. Wingert and T. S. Danowski* 741

Growth Hormone in Insulin-Treated Diabetes Mellitus
G. Sabeh, L. V. Mendelsohn, D. G. Corredor, J. H. Sunder, L. M. Friedman, C. R. Morgan and T. S. Danowski 748

Enhanced Postglucose Hypophosphatemia During Starvation Therapy of Obesity ..... *D. G. Corredor, G. Sabeh, L. V. Mendelsohn, R. E. Wasserman, J. H. Sunder and T. S. Danowski* 754

Insulin Responses in Mytonia Dystrophica ..... *L. V. Mendelsohn, L. M. Friedman, D. G. Corredor, J. C. Sieracki, G. Sabeh, J. W. Vester and T. S. Danowski* 764

Preliminary Report: Carbohydrate Intolerance in Gout *Gustave Denis and Marc P. Launay* 770

Effect of Glucose on Liver Metabolism During Ethanol Oxidation ..... *Olof A. Forsander and Jaakko-Juhani Himberg* 776

Hormone Production by Human Pituitary Adenomas in Culture *Peter O. Kohler, William E. Bridson, Phillip L. Rayford and Stewart E. Kohler* 782

Deficient Thiamine Pyrophosphate and Blood Alpha-Ketoglutarate-Pyruvate Relationships During Febrile Human Infections ..... *V. E. Gilbert, M. C. Susser and A Nolte* 789

Effect of Centrophenoxine Hydrochloride on Thyroxine Metabolism in the Rat ..... *Isao Kobayashi, Takashi Yamada and Kojiro Shichijo* 800

No. 10 (October)

Serum Growth Hormone and Insulin in Females Without Glucose Intolerance ..... *T. S. Danowski, C. T. Tsai, C. R. Morgan, J. C. Sieracki, R. A. Alley, T. J. Robbins, G. Sabeh and J. H. Sunder* 811

Hyponatremia in Pituitary Insufficiency *Bernard B Davis, Marvin E. Bloom, James B. Field and Daniel H. Mintz* 821

Plasma Triglycerides in Genetically Obese Rats *Wayne S. Barry and George A. Bray* 833

Lipid Mobilization in Relation to Body Composition in Man *Per Björntorp, Halvar Bergman, Edvardas Varnauskas and Björn Lindholm* 840

New Lipoprotein Differing in Charge and Density from Known Plasma Lipoproteins ..... *H. S. Sodhi* 852

Glycine Loading Test in Acute Intermittent Porphyria Patients and Their Relatives *D. Lynn Loriaux, Sylvia Deleña and Harold Brown* 860

Thiazide-induced Parathyroid Stimulation *Jack R. Pickleman, Francis H. Straus II, Marvin Forland and Edward Paloyan* 867

Chlorpropamide in Idiopathic Diabetes Insipidus *Domenico Andreani, Giulio Alberto Cinotti and Giovanni Stirati* 874

No. 11 (November)

EDITORIAL 879

RADIOGRAPHIC DETERMINATION OF ACHILLES TENDON XANTHOMA SIZE
David H. Blankenhorn and Harvey I. Meyers 882

EFFECT OF FASTING ON ESTERIFIED α-GLYCEROL ETHERS OF THE NEUTRAL LIPIDS OF HEART AND ADIPOSE TISSUE OF RATS
John R. Gilbertson 887

IN VITRO METABOLIC EFFECTS OF PROTEOLYTIC DIGESTS OF BOVINE GROWTH HORMONE IN ADIPOSE TISSUE ..... *Norbert I. Swislocki* 895

EFFECT OF GLYCINE LOADING ON DELTA-AMINOLEVULINIC ACID (ALA) AND PORPHOBILINOGEN (PBG) EXCRETION DURING STARVATION
Sylvia Deleña and Harold Brown 901

ANTI-LIPOLYTIC EFFECTS OF β-HYDROXYBUTYRATE
Dorothea E. Hellman, Boris Senior and H. Maurice Goodman 906

THE EFFECT OF [4,4′-(ISOPROPYLIDENEDITHIO)BIS(2,6-DI-T-BUTYLPHENOL)] (DH-581) ON SERUM LIPIDS AND LIPOPROTEINS IN HUMAN SUBJECTS ..... *John W. Drake, Reagan H. Bradford, Marvin McDearmon and Robert H. Furman* 916

MECHANISM OF ACTION OF ANTILIPOLYTIC AGENTS: COMPARISON OF THE EFFECTS OF INSULIN, TOLBUTAMIDE, AND PHENFORMIN ON LIPOLYSIS INDUCED BY DIBUTYRYL CYCLIC AMP PLUS THEOPHYLLINE
Joseph D. Brown, Daniel B. Stone and Ann A. Steele 926

ACTIONS OF GROWTH HORMONE: ENHANCEMENT OF INSULIN UTILIZATION WITH INHIBITION OF INSULIN EFFECT ON BLOOD GLUCOSE IN DOGS
James Campbell and Krishna Sudha Rastogi 930

EXCESSIVE FLUID RETENTION RELATED TO CELLULOSE INGESTION: STUDIES ON TWO PATIENTS ..... *Milton G. Crane, John J. Harris, Raymond Herber, Stewart Shankel and Norman Specht* 945

EFFECTS OF ADRENERGIC BLOCKING AGENTS OF BASAL AND STIMULATED THYROID FUNCTION ..... *Gerald Burke* 961

RENAL CORTICAL ADENYL CYCLASE: EFFECTS OF PARATHYROID HORMONE AND CALCIUM ..... *James M. Streeto* 968

No. 12 (December)

EDITORIAL 975

LIPEMIA RETINAIS: MICROCIRCULATORY CHANGES AND LIPID STUDIES IN A FAMILY ..... *Bernard I. Chazan, B. Dan Ferguson, William P. Castelli, Jens N. F. Touborg, Marios C. Balodimos and D. D. Rutstein* 978

EFFECT OF WEIGHT REDUCTION, TRIIODOTHYRONINE, AND DIETHYLSTILBESTROL ON GROWTH HORMONE IN OBESITY
Javier H. Londono, Thomas F. Gallagher, Jr. and George A. Bray 986

Serum Growth Hormone Level after Oral Glucose Load, Urinary Excretion of Pituitary Gonadotrophin and 17-Ketosteroids in XYY Syndrome ..... *J. Nielsen, H. Yde and K. Johansen* 933

Obesity and Insulin Resistance in the Obese-Hyperglycemic Mouse (obob) ..... *C. Chlouverakis and P. A. White* 998

Effect of Coffee Ingestion on Adrenocortical Secretion in Young Men and Dogs ..... *Samuel Bellet, John Kostis, Laurian Roman and Oscar DeCastro* 1007

Response of Growth Hormone (GH), FFA, Blood Sugar and Insulin to Exercise in Obese Patients and Normal Subjects *F. Schwarz, D. J. ter Haar, H. G. van Riet and J. H. H. Thijssen* 1013

Different Rate of Incorporation of Glucose and Fructose into Plasma and Liver Lipids in Guinea Pig *Muriel M. Gale and M. A. Crawford* 1021

Instantaneous and Continuous Measurement of ^{14}C-labeled Substrate Oxidation to $^{14}CO_2$ by Human Surgical Biopsy Specimens: An Ionization Chamber Method *Warren D. Davidson, Thomas C. Moore, Richard J. Glassock and James C. Thompson* 1026

Red Cell in Vitro Metabolism in Approximate Steady-State *John J. Imarisio, Barry Gendelman and James A. Strother* 1033

Calcium and Magnesium Excretion During Glucose and Mercaptomerin Diuresis in Man ..... *Joseph M. Letteri and Laurence G. Wesson, Jr.* 1048

Effects of Hypoxia and Dietary Aspirin on Plasma and Urinary Amino Acids in the Rat ..... *David A. Vaughan, Patricia R. Korty and John L. Steele* 1055

Serum Gonadotropin and Testosterone Levels in Uremic Males Undergoing Intermittent Dialysis *Amelia Guevara, D. Vidt, Marvin C. Hallberg, Elinor M. Zorn, Carol Pohlman and Ralph G. Wieland* 1062

AUTHOR INDEX

Adams, W. P., 209
Ahuja, M. M. S., 488
Albert, M., 635
Alcock, N. W., 115
Alderman, M. H., 692
Alexander, R. W., 248
Alexander, W. D., 58
Alley, R. A., 811
Almogela, E., 84
Andreani, D., 874
Appleton, H., 300
Arky, R. A., 6, 103
Armitage, J. L., 81

Bacchus, H., 277
Baker, L., 110
Balcerzak, S. P., 1
Balodimos, M. C., 978
Barbosa, J., 141
Barham, F., 484
Barry, K. G., 445
Barry, W. S., 833
Bass, D. E., 349
Beeler, M. F., 646
Bell, J. D., 193
Bellamy, H. M., 675
Bellet, S., 163, 288, 484, 1007
Bergman, H., 840
Birkenhäger, J. C., 18
Björntorp, P., 840
Blackard, W. G., 226
Blankenhorn, D. H., 882
Blizzard, R. M., 234
Bloom, M. E., 821
Bolinger, R. E., 172
Bortz, W. M., 120
Bradford, R. H., 917
Bradley, E. M., 675
Bray, G. A., 833, 986
Bridson, W. E., 782
Brooks, M. H., 445
Brown, D. C., 669
Brown, H., 860, 901
Brown, J. D., 926
Bryant, M., 439
Buchanan, K. D., 155
Burke, G., 132, 720, 961
Burns, M. J., 427

Cabrejas, M. L., 395
Calloway, D. H., 193
Campbell, J., 930
Carroll, B. J., 476
Castelli, W. P., 978
Cavalieri, R. R., 148
Chazan, B. I., 978
Chlouverakis, C., 998
Choitz, H. C., 416
Chopra, I. J., 488
Cinotti, G. A., 874
Cohen, P., 38
Corredor, D. G., 731, 741, 748, 754, 764
Cowan, J. S., 319
Craig, J. W., 460
Crane, M. G., 945
Crawford, M. A., 1021

Danforth, Jr., E., 445
Danowski, T. S., 1, 731, 741, 748, 754, 764, 811
Davidson, M. B., 387
Davidson, W. D., 1026
Davis, B. B., 821
Day, E. A., 646
DeCastro, O., 288, 1007
DeCastro, O. A. P., 163
DeGroot, L. J., 331
Deleña, S., 860, 901
DeLeon, V., 509
Denis, G., 770
de Romero, S. A. D., 292
Drake, J. W., 916
Drane, J. W., 519
Dulin, W. E., 214
Dyerberg, J., 50

Edgar, P., 84
Eichenholz, A., 252
Eriksson, O., 713

Faircloth, M. A., 311
Feinberg, L. J., 163
Ferguson, B. D., 978
Field, J. B., 821
Firschein, H. E., 115
Florsheim, W. H., 311
Foa, P. P., 433
Forland, M., 867
Forsander, O. A., 776
Forsham, P. H., 175, 248
Friedman, L. M., 748, 764
Frimpter, G. W., 692
Fukuda, H., 339
Furman, R. H., 916

Gaebler, O. H., 416
Gale, M. M., 1021
Gallagher, Jr., T. F., 986
Gendelman, B., 1033
Genuth, S. M., 124
Gerritsen, G. C., 214
Gilbert, V. E., 789
Gilbertson, J. R., 887
Gilder, H., 509
Glassock, R. J., 1026
Goldsmith, R. S., 349
Goodman, H. M., 906
Gould, R. G., 652
Gregory, D. H., 252
Grimaldi, R. D., 406
Grodsky, G. M., 248
Guevara, A., 1062
Guha, A., 445
Gulli, R., 148
Gutstein, W. H., 300

Haddad, J. G., 71
Hallberg, M. C., 1062
Hampers, C. L., 387
Haque, N., 110
Harden, R. McG., 58
Harris, J. J., 945
Hartsuck, J. M., 33, 663
Heidingsfelder, S. A., 226
Hellman, D. E., 906
Herber, R., 945
Himberg, J., 776
Hoffman, R. S., 103
Holmes, W. L., 120
Hoshi, M., 422
Howat, P., 120
Hultberg, B., 713

Imarisio, J. J., 1033
Ingbar, S. H., 349
Isaacs, M., 692

Jackson, I., M.D., 13
Jagger, P. I., 369
Johansen, K., 993
Johanson, A., 234

Johnson, B. F., 87
Johnson, J. E., 33, 663
Jones, R. J., 652
Jung, W. F., 406

Kaye, R., 110
Kent, J. R., 241
Kershbaum, A., 288
Killian, P., 349
Kim, K. E., 288
Knudsen, K. B., 675
Kobayashi, I., 800
Kohler, P. O., 782
Kohler, S. E., 782
Kokatnur, M. G., 73
Korty, P. R., 1055
Kostenbauder, H., 209
Kostis, J., 1007
Kretchmar, A. L., 684
Kuo, P. T., 631

Landau, R. L., 265
Lauler, D. P., 369
Launay, M. P., 770
Lecocq, F. R., 675
Leonards, J. R., 124
LeRoy, G. V., 652
Letteri, J. M., 1048
Light, C., 234
Lindholm, B., 840
Lombardo, Y. B., 731
Londono, J. H., 986
Loriaux, D. L., 860
Lowrie, E. G., 387
Lugibihl, K., 265

Malcom, G. T., 73, 646
Margen, S., 193
Marshall-Jones, P., 700
Martin, F. I. R., 476
Martinez, R. D., 73
Mautalen, C. A., 395
McDermon, M., 916
McLarty, D., 58
Meek, J. C., 172
Mendelsohn, L. V., 731, 741, 748, 754, 764
Merimee, T. J., 84
Meyers, H. I., 882
Migeon, C. J., 234
Miller, M., 376
Mintz, D. H., 821
Mirise, R. T., 311
Moore, F. D., 33, 663
Moore, T. C., 1026
Morgan, C. R., 731, 741, 748, 811
Moses, A. M., 376
Mulhausen, R., 669

Nicholas, G., 38
Nielsen, J., 993
Nolte, A., 789

Oakes, D. D., 103
Ochi, Y., 331
Öckerman, P., 713
Oliner, I., 141
Olsen, W., 6
Onstad, G., 669
Owen, J. A., 71

Paloyan, E., 867
Parra, A., 497
Pavlatos, F. Ch., 175
Pearson, M. J., 476
Penhos, J. C., 87
Pickeleman, J. R., 867
Plummer, A. L., 469
Pohlman, C., 1062
Price, E. J., 684

Rabinowitz, D., 84
Raiti, S., 234
Randall, R. V., 469
Rastogi, K. S., 930
Rayford, P. L., 782
Reidenberg, M. M., 209
Reyes, R., 439
Rieselbach, R. E., 63
Riggs, B. L., 469
Robbins, T. J., 811
Rodgers, D., 439
Roman, L., 288, 484, 1007
Root, A. W., 110
Rose, L. I., 369
Rosenberg, C. A., 87
Ross, E. J., 700
Rossen, R. M., 433
Rutstein, D. D., 978

Sabeh, G., 1, 731, 741, 748, 754, 764, 811
Samaan, N. A., 460
Sanbar, S. S., 292
Sandberg, H., 163
Scheiner, E., 692
Schneck, D. J., 300
Schreibman, P. H., 103
Schultz, R. B., 497
Schutta, H. S., 81
Schwarz, F., 1013
Searle, G. L., 148
Self, K. S., 427
Senior, B., 906
Shankel, S., 945
Shelp, W. D., 63
Shichijo, K., 339, 800
Shimmins, J., 58
Shreeve, W. W., 422
Sieracki, J. C., 741, 764, 811
Smilo, R. P., 175
Smith, R., 700
Sodhi, H. S., 852
Sodoyez, J., 433
Sodoyez-Goffauz, F., 433
Soto, R. J., 395
Sparks, L. L., 175
Specht, N., 945
Sridhar, C. B., 488
Stansell, M. J., 635
Steele, A. A., 926
Steele, J. L., 1055
Steele, T. H., 63
Sternberg, D., 509
Stirati, G., 874
Stone, D. B., 926
Streeto, J. M., 968
Straus II, F. H., 867
Strother, J. A., 1033
Sunder, J. H., 741, 748, 754, 811
Suryanarayana, B. V., 241
Susser, M. C., 789
Swislocki, N. I., 895
Szabo, A. J., 406

Takemura, Y., 339
Taylor, C. B., 652
ter Haar, D. J., 1013
Thijssen, J. H. H., 1013
Thompson, J. C., 1026
Thorn, G. W., 369
Tjabbes, T., 18
Touborg, J. N. F., 978
Tsai, C. T., 811

Valcic, M., 509
Vance, J. E., 155
van Riet, H. G., 1013
Varnauskas, E., 840
Vaughan, D. A., 1055
Vertes, V., 124
Vester, J. W., 1, 764
Veverbrants, E., 6
Vidt, D., 1062
Viktora, J. K., 87
Vogler, W. R., 519
Vranic, M., 319

Walker, Jr., F. E., 252
Wasserman, R. E., 754
Waugh, W. H., 706
Weinstein, J. J., 445
Wesson, Jr., L. G., 1048
Whang, R., 439
White, P. A., 998
Wieland, R. G., 1062
Williams, A. D., 311
Williams, H., 369
Williams, R. H., 155
Wingert, J. P., 741
Wissler, R. W., 652
Wolff, F. W., 87
Wrenshall, G. A., 319
Yamada, T., 339, 800
Yde, H., 993
Zahradnik, J. M., 172
Zollinger, Jr., R. M., 663
Zorn, E. M., 1062

Index of Subjects

Absorption
of bicarbonate, in tubular acidosis, 252–263
of calcium, 395–404
after dialysis for renal failure, 124–130
of fat, with cellulose-free diet, 956
of glucose, drugs affecting, 599–604
of β-sitosterol, 652–661
Acetate, inhibiting lipolysis, 913
Acetylsalicylic acid. *See* Salicylates
Achilles tendon xanthoma, radiography of, 882–885
Acidosis, proximal tubular, secondary, 252–263
Acromegaly, with anterior pituitary failure, 469–475
ACTH
affecting thyroxine uptake by muscle, 342
diphenylhydantoin affecting release of, 374
levels in Cushing's syndrome, 175–191
lipolytic response to, 926–929
β-hydroxybutyrate affecting, 910
salicylate affecting, 620–623
reserves of, after dexamethasone, 376–385
test with, in lung cancer, 612
Adenine nucleotides, affecting thyroid hormone release, 331–336
Adenoma, pituitary, hormone production by, 782–788
Adenosine monophosphate, cyclic
lipolytic response to, 926–929
β-hydroxybutyrate affecting, 906–913
salicylate affecting, 620–623
parathyroid hormone affecting excretion of, 968–972
and thyroid function, 961–966
Adenosine triphosphate, in red cells, 1042–1045
Adenyl cyclase
and inhibition of lipolysis, 926–929
renal cortical, parathyroid hormone affecting, 968–972
role in thyroid stimulation, 961–966
See also Adenosine monophosphate, cyclic
Adipose tissue
glycerol ethers of lipids in, 887–893
proteolytic digests of bovine growth hormone in, 895–899
Adrenal glands
alternate pathways for corticosteroid excretion, 277–286
coffee ingestion affecting cortical secretion, 1007–1011
cortical function in lung cancer, 609–618
exercise affecting corticosteroid excretion, 484–486
hypothalamic-pituitary-adrenal function tests, 376–385, 476–482
paradoxical dexamethasone response, 369–374
vasopressin release after glucocorticoids, 821–831
Adrenalectomy, affecting thyroid function in starvation, 311–317
Adrenergic blockade
affecting FFA rebound after nicotinic acid, 226–232
affecting insulin levels in pheochromocytoma, 453, 455–456
affecting thyroid function, 961–966
Adrenergic drugs, and epinephrine-induced metabolic responses, 497–506
Alanine in plasma, glucagon affecting, 265–275
Alcohol
ingestion of, and urine dilution after dexamethasone, 826–827, 830
oxidation of, liver metabolism in, glucose affecting, 776–780
Aldosterone excretion
in fluid retention after cellulose ingestion, 945–960
in pheochromocytoma, 453
in water diet for obesity, 700–705

Allopurinol, and ammonia excretion in gout, 519–543
Altitude, high, amino acid levels in, 1044–1061
Amino acids
  acetylsalicylic acid affecting levels of, 1044–1061
  dietary, affecting cholesterol and bile acid metabolism, 427–431
  glucagon affecting, in plasma, 265–275
  and growth hormone release, 456
  hypoxia affecting levels of, 1044–1061
  iodinated, affecting serum creatine phosphokinase in muscular dystrophy, 1–5
  route of administration affecting metabolism of, 416–421
  urinary, in storage disorders, 713–719
δ-Aminolevulinic acid excretion in glycine loading test, 860–865
  in starvation, 901–905
Ammonia excretion in gout, allopurinol affecting, 519–543
Ammonium chloride, and uric acid excretion in gout, 519–543
Amylase, renal clearance of, in pancreatitis, 669–673
Androgens
  affecting growth hormone secretion, 817
  excretion in XYY syndrome, 993–996
Antidiuretic hormone. *See* Vasopressin
Arginine
  and epinephrine infusions in obese adolescents, 497–506
  glucagon affecting, in plasma, 265–275
  and growth hormone levels, 456
    in menstrual cycle, 606–607
    in obesity, 986–991
    testosterone affecting, 817
  and insulin release, 84–86, 452
  responses to, in obesity, 754–762
DL-Arterenol, lipolytic response to, 926–929
  salicylate affecting, 620–623
Atherosclerosis
  clofibrate in, 635–644
  metabolic basis of, 631–633
Azotemia, drug metabolism in, 209–212

Bicarbonate absorption, in tubular acidosis, 252–263
Bile acid metabolism, dietary compounds affecting, 427–431
Biliary system, extrahepatic, and plasma lipids after brain stimulation, 300–309
Biliary transport, and sulfobromophthalein retention in fasting, 675–682
Biopsy specimens, ionization chamber for studies of, 1026–1032
Body composition
  diet affecting, after injury, 509–517
  and lipid mobilization, 840–849
  after starvation and refeeding, 564–569
Bone
  cell metabolism in multiple myeloma, 38–49
  collagen and mineral removal from, 115–118
  glycylproline peptiduria in familial hyperostosis, 692–698
  osteolytic sterols in tumors, 646–651
  potassium in, 33–37
  zinc deposition in, vitamin D affecting, 625–628
Brain stimulation, affecting plasma lipids, 300–309
Breast tumors, sterols in, 646–650
Bromsulphalein retention, in fasting, 675–682
Burns, hyperglycemic, nonketotic coma in, 103–108
Butyrate, inhibiting lipolysis, 913

Caffein, routes of administration affecting glucose tolerance tests, 163–169
Caffeinated beverages
  affecting adrenocortical secretion, 1007–1011
  affecting catecholamine release, 288–291, 1011
Calcium
  affecting renal cortical adenyl cyclase, 968–972
  in bone, vitamin D affecting, 627
  diuretics affecting excretion of, 1048–1053
  intestinal absorption of, 395–404
    after dialysis for renal failure, 124–130
  phosphate supplements affecting balance of, in immobilization, 349–366
  thiazide affecting levels of, 867–872
Campesterol, in tumors, 646–650
Capillary changes, and atherogenesis, 632–633
Carbimazole, thyroid function after, 58–62
Carbohydrates
  metabolism of
    in atherosclerosis, 631–633
    pyrazinamide affecting, 214–224
    in type III hyperlipoproteinemia, 53–54, 56

preventing starvation ketosis, 193–208
See also Glucose
2-Carboxypyrazine, affecting glucose levels, 214–224
Cartilage, collagen and mineral removal from, 115–118
Catecholamines
caffeine affecting levels of, 288–291, 1011
excretion in pheochromocytoma, 453–454
See also Epinephrine
Cellulose ingestion, and fluid retention, 945–960
Centrophenoxine hydrochloride, affecting thyroxine metabolism, 800–810
Chlorpropamide, in diabetes insipidus, idiopathic, 874–877
Cholesterol levels
after brain stimulation, 300–309
caffeine affecting, 1011
clofibrate affecting, 635–644
DH-581 affecting, 916–925
dietary compounds affecting, 427–431
ethyl-p-chlorophenoxyisobutyrate affecting 73–79
in genetically obese rats, 833–839
in hypothyroidism of childhood, 494
low calorie diet affecting, in obesity, 208
Chorionic somato-mammotropine, human, 593–597
Chromosomes, in XYY syndrome, 993–996
Chylomicrons in plasma, and lipemia retinalis, 978–984
Citrulline in plasma, glucagon affecting, 265–275
Clofibrate
affecting lipid levels, 73–79
affecting thyroxine levels, 141–146
in vascular disease, 635–644
Coffee ingestion. *See* Caffeinated beverages
Cold, affecting protein-thyroxine interaction, 339–346
Collagen
metabolism disorders of, and glycylproline peptiduria, 692–698
removal from bone and cartilage, 115–118
Cologel, and fluid retention, 945–960
Coma, hyperglycemic, nonketotic, in burns, 103–108
Coronary heart disease, metabolic basis of, 631–633
Corticosteroid excretion, alternate pathways for, 277–286
Cortisol
plasma levels
in lung cancer, 610–611
vasopressin affecting, 241–246
therapy with, glucose and insulin infusions with, 277–286
Creatine phosphokinase in muscular dystrophy, iodinated amino acids affecting, 1–5
Creatinine, renal clearance of, in pancreatitis, 669–673
Cretinism, sporadic, and juvenile hypothyroidism, 488–495
Cushing's syndrome
ACTH levels in, 175–191
metyrapone test in, 175–191
Cystine
affecting cholesterol and bile acid metabolism, 427–431
glucagon affecting, in plasma, 265–275

Danabol, effects in starvation, 585–591
Desmosterol, in tumors, 646–651
Dexamethasone
affecting adrenal cortex response to ACTH, 616
and glucose tolerance test, and early insulin response to glucose load, 248–251
in hyponatremia with pituitary insufficiency, 821–831
lipolytic response to, 926–929
salicylate affecting, 620–623
paradoxical response to, 369–374
pituitary reserve assessment after, 376–385
DH-581, affecting lipid levels, 916–925
Diabetes
DH-581 affecting lipid levels in, 916–925
and gout, 770–774
growth hormone levels during insulin therapy, 748–752
insipidus, idiopathic, chlorpropamide in, 874–877
insulin levels before and after onset of, 731–738
juvenile
growth hormone role in, 110–114
metabolic homeostasis in, 110–114
lipemia retinalis in, 978–984
lipoatrophic, 545–555
insulin and growth hormone levels in, 460–467
and urinary diabetogenic peptide in proteinuria, 556–562
steroid-stress, and early insulin response to glucose load, 248–251
vasopressin affecting glucose levels in, 241–246
See also Glucose; Insulin

Diabetogenic polypeptide in urine. *See* Diabetes, lipoatrophic
Dialysis for renal failure
  calcium absorption after, 124–130
  and endocrine disorders in men, 1062–1066
Diazoxide, affecting insulin release, 11
Dichlorisoproterenol, affecting glucose oxidation, 965
Diet
  and body composition after injury, 509–517
  cellulose ingestion and fluid retention, 945–960
  compounds affecting cholesterol and bile acid metabolism, 427–431
  and fasting, affecting glucose turnover, 319–329
  fats in, and ethyl-p-chlorophenoxyisobutyrate activity, 73–79
  feeding frequency affecting daily FFA levels, 120–122
  in obesity, affecting blood constitutents, 193–208
  phosphate supplements in immobilization, 349–366
  vitamin D affecting zinc deposition in bon, 625–628
  water diet in obesity, aldosterone and sodium excretion in, 700–705
  See also Starvation
Diethylstilbestrol, affecting growth hormone in obesity, 986–991
Diphenylhydantoin, affecting adrenal function, 374
Diuretics, affecting calcium and magnesium excretion, 1048–1053
Drug metabolism, in obesity and azotemia, 209–212
Duncan, Garfield, G., 975–977
Dystrophy, muscular, iodinated amino acids in, affecting serum creatine phosphokinase, 1–5

Edema, and cellulose ingestion, 945–960
Electrometer, vibrating reed, for biopsy specimen studies, 1026–1031
Endocytosis, adrenergic blocking agents affecting, 965
Epinephrine
  affecting thyroxine uptake by muscle, 343–344
  excretion of, coffee ingestion, 288–291
  infusions of, in obese adolescents, 497–506
  lipolytic response to, β-hydroxybutyrate affecting, 906–913
  plasma lipid response to, adrenal role in, 1011
Erythrocytes
  metabolism in vitro, 1033–1046
  transketolase in, in thiamine deficiency, 789–797
Estrogen, and growth hormone responses, 606–607, 990
Ethanol. *See* Alcohol
Ethylchlorophenoxyisobutyrate. *See* Clofibrate
Exercise
  affecting adrenocortical excretion, 484–486
  in obesity, metabolic effects of, 1013–1019

Fasting. *See* Starvation
Fat
  absorption studies, with cellulose-free diet, 956
  dietary, and action of ethyl-p-chlorophenoxyisobutyrate, 73–79
  pyrazinamide affecting metabolism of, 214–224
Fatty acids, free
  in fat cells
    human chorionic somato-mammotropine affecting release of, 593–597
    salicylate affecting lipolysis in, 620–623
  in new lipoprotein, 857–858
  placental transport of, 406–414
  plasma levels
    agents affecting, comparison of, 926–929
    caffeine affecting, 1011
    after epinephrine infusions in obese adolescents, 497–506
    exercise affecting, in obesity, 1013–1019
    feeding frequency affecting daily levels of, 120–122
    and glucose turnover, 570–582
    hydralazine affecting, 292–298
    β-hydroxybutyrate affecting, 906–913
    in obesity, 840–849
    pyrazinamide affecting, 214–224
    rebound after nicotinic acid, adrenergic blockade affecting, 226–232
    response to insulin, growth hormone affecting, 941
    after trauma, diet affecting, 509–517
    turnover rates and esterification of, in obesity, 18–31

Febrile infections, and thiamine pyrophosphate deficiency, 789–797
Feeding frequency, affecting daily FFA levels, 120–122
Fluid retention, and cellulose ingestion, 945–960
9 α-Fluorohydrocortisone, in hyponatremia with pituitary insufficiency, 821–831
Follicle-stimulating hormone
  levels after dialysis in males, 1062–1066
  radioimmunoassay of, 234–239
Fructose, incorporation into plasma and liver lipids, 1021–1025

Galactose, intracellular, pyrazinamide affecting, 214–224
Gastrointestinal tract
  in hypoglycemia, reactive, 6–11
  insulinogenic effect of gut loop material, 71–72
  See also Absorption
Gaucher's disease, urinary amino acids in, 713–719
Genetic obesity, plasma triglycerides in, 833–839
Glucagon
  affecting amino acids in plasma, 265–275
  insulin responses to, in myotonia dystrophica, 764–768
  lipolytic response to, 926–929
    β-hydroxybutyrate affecting, 910
    salicylate affecting, 620–623
  responses to, in obesity, 754–762
  starvation affecting release of, 155–160
Glucocorticoids, affecting vasopressin release, 821–831
Glucose
  absorption of, drugs affecting, 599–604
  affecting liver metabolism in ethanol oxidation, 776–780
  blood levels
    2-carboxypyrazine affecting, 214–224
    exercise affecting, in obesity, 1013–1019
    feeding frequency affecting daily levels of, 120–122
    growth hormone affecting, 941
    hydralazine affecting, 292–298
    induced hypoglycemia after dexamethasone, 376–385
    low calorie diet affecting, in obesity, 207–208
    mannoheptulose affecting, 87–101, 422–425
    phenformin affecting, in nondiabetic humans, 148–153
    pyrazinamide affecting, 214–224
    reactive hypoglycemia, gastrointestinal factors in, 6–11
    after trauma, diet affecting, 509–517
    vasopressin affecting, 241–246
  diuresis from, calcium and magnesium excretion in, 1048–1053
  hyperglycemic, nonketotic coma in burns, 103–108
  incorporation into plasma and liver lipids, 1021–1025
  insulin with
    affecting magnesium and potassium levels, 439–443
    after cortisol therapy, 277–286
    early insulin response to, in steroid-stress diabetes, 248–251
  metabolism in adipose tissue, proteolytic digests of bovine growth hormone affecting, 895–899
  obese-hyperglycemic mice
    insulin resistance in, 998–1005
    mannoheptulose effects in, 422–425
  oxidation of, adrenergic blocking agents affecting, 963–964
  in red cells, 1037–1040
  tolerance tests
    in atherosclerosis, 631–633
    caffeine administration routes affecting, 163–169
    in gout, 770–774
    and growth hormone levels, 811–818
      in XYY syndrome, 993–996
    and insulin levels, 811–818
      before and after diabetes onset, 731–738
      in myotonia dystrophica, and insulin responses, 764–768
    newly-identified intolerance, growth hormone and insulin levels in, 741–746
    in pheochromocytoma, 445–457
    in starvation, and hypophosphatemia, 754–762
    in uremia, 387–393
  turnover of
    diet and fasting affecting, 319–329
    in lean and obese humans, 570–582
Glycerol ethers of lipids, in adipose tissue, 887–893
Glycerol release
  affected by proteolytic digests of bovine growth hormone, 895–899
  agents affecting, comparison of, 826–929
  and body fat weight, 840–849
  human chorionic somato-mammotropine affecting, 593–597

β-hydroxybutyrate affecting, 906–913
sodium salicylate affecting, 620–623
Glycine
loading test
in acute intermittent porphyria, 860–865
affecting excretion of PBG and ALA in starvation, 901–905
nitrogen from, metabolism of, 416–421
in plasma, glucagon affecting, 265–275
Glycogen in liver and muscle, pyrazinamide affecting, 214–224
Glycylproline peptiduria, in familial hyperostosis, 692–698
Goldblatt kidney, after pheochromocytoma removal, 445–457
Gonadotropin
excretion in XYY syndrome, 993–996
levels after dialysis in males, 1062–1066
Gout
ammonia excretion in, allopurinol affecting, 519–543
carbohydrate intolerance in, 770–774
Growth hormone
affecting FFA rebound after nicotinic acid, 226–232
affecting insulin utilization, 930–942
blood levels
after dexamethasone, 376–385
in females without glucose intolerance, 811–818
in insulin-treated diabetes, 748–752
in lipoatrophic diabetes, 460–467
in newly-identified glucose intolerance, 741–746
in obesity
agents affecting, 986–991
exercise affecting, 1013–1019
in pheochromocytoma, 445–457
vasopressin affecting, 241–246
in XYY syndrome, 993–996
bovine, proteolytic digests of, in adipose tissue, 895–899
lipolytic response to, 926–929
salicylate affecting, 620–623
produced by pituitary adenomas, 782–788
role in juvenile diabetes, 110–114
secretion during menstrual cycle, 606–607
Gut loop material, serosal, insulinogenic effect of, 71–72
Gynecomastia, after dialysis in males, 1062–1066

Heart
coronary disease, metabolic basis of, 631–633
glycerol ethers in lipids of, 887–893
Hemodialysis. *See* Dialysis
Histidine
incorporation into protein, proteolytic digests of bovine growth hormone affecting, 895–899
in plasma, glucagon affecting, 265–275
Hydralazine, affecting glucose and FFA levels, 292–298
Hydrochlorothiazide, parathyroid stimulation from, 867–872
Hydrocortisone, in hyponatremia with pituitary insufficiency, 821–831
β-Hydroxybutyrate, antilipolytic effects of, 906–913
11-Hydroxycorticosteroid excretion
caffeine affecting, 1007–1011
exercise affecting, 484–486
in lung cancer, 612–613
17-Hydroxycorticosteroids
in plasma
dexamethasone affecting, 376–385
in pheochromocytoma, 454
urinary
in lung cancer, 612
paradoxical rise in, after dexamethasone, 369–374
in pheochromocytoma, 454
Hydroxyprolinuria, in familial hyperostosis, 692–698
Hyperlipoproteinemia, type III, 50–57
Hypothalamic-pituitary function, testing of, 376–385, 476–482
Hypothalamic stimulation, affecting plasma lipids, 300–309
Hypoxia, amino acid levels in, 1044–1061

Immobilization, phosphate supplements in, 349–366
Immunoassay, of follicle-stimulating hormone, 234–239
Infections, febrile, and thiamine pyrophosphate deficiency, 789–797
Insulin
blood levels
arginine affecting, 84–86
in atherosclerosis, 631–633
before and after diabetes onset, 731–738
and body fat weight, 840–849
early response to glucose load in steroid-stress diabetes, 248–251
after epinephrine infusions in obese adolescents, 497–506
in females without glucose intolerance, 811–818

in lipoatrophic diabetes, 460–467
mannoheptulose affecting, 87–101, 422–425
in myotonia dystrophica, 764–768
in newly-identified glucose intolerance, 741–746
in obesity, exercise affecting, 1013–1019
in pheochromocytoma, 445–457
starvation affecting, 155–160
vasopressin affecting, 241–246
glucose with
affecting magnesium and potassium levels, 439–443
after cortisol therapy, 277–286
growth hormone affecting utilization of, 930–942
and growth hormone levels
in diabetes, 748–752
in obesity, 986–991
inhibiting lipolysis, 913, 926–929
in islet-cell tumors, transplantable, 433–437
lack of antagonist of, in uremia, 387–393
resistance to, in obese-hyperglycemic mice, 998–1005
secretion of
A and B chain production, 172–174
gastric emptying affecting, 6–11
tolerance test, of hypothalamic-pituitary-adrenal function, 476–482
Insulinogenic effect, of serosal gut loop material, 71–72
Intestinal absorption. *See* Absorption
Iodinated amino acids, affecting serum creatine phosphokinase in muscular dystrophy, 1–5
Ionization chamber, in biopsy specimen studies, 1026–1032
Islet-cell tumors, and insulin release, 433–437
Isoleucine in plasma, glucagon affecting, 265–275

α-Ketoglutarate levels, in febrile infections, 789–797
Ketone bodies, inhibiting lipolysis, 906–913
Ketosis, from low calorie diet in obesity, 193–208
17-Ketosteroid excretion, in XYY syndrome, 993–996
Kidney
amylase clearance in pancreatitis, 669–673
cortical adenyl cyclase, 968–972
dialysis for renal failure
calcium absorption after, 124–130
and endocrine disorders in men, 1062–1066
function studies in cellulose-free diet, 956
glucocorticoids affecting tubule sodium reabsorption, 821–831
proximal tubular acidosis, secondary, 252–263
See also Uremia
Kininogen depletion, from cellulose, 959
Kinsell, L. W., 57

Lactic acid
inhibiting lipolysis, 913
in red cells, 1037–1040
Leucine in plasma, glucagon affecting, 265–275
Leucodystrophy, metachromatic, urinary amino acids in, 713–719
Leydig cell function, after dialysis in males, 1062–1066
Lipemia retinalis, 978–984
Lipids
in adipose tissue, glycerol ethers of, 887–893
blood levels
after brain stimulation, 300–309
caffeine affecting, 1011
clofibrate affecting, 73–79, 635–644
DH-581 affecting, 916–925
in obesity, starvation affecting, 13–16
in liver and plasma, glucose incorporation into, 1021–1025
metabolism in atherosclerosis, 631–633
mobilization of, and body composition, 840–849
Lipoatrophic diabetes, 545–555
insulin and growth hormone levels in, 460–467
and urinary diabetogenic peptide in proteinuria, 556–562
Lipolysis
antilipolytic effects of β-hydroxybutyrate, 906–913
comparison of antilipolytic agents, 926–929
by human chorionic somato-mammotropine, 593–597
salicylate affecting, in isolated fat cells, 620–623
Lipoproteins
caffeine affecting, 1011
DH-581 affecting, 916–925
new lipoprotein, 852–859
type III hyperlipoproteinemia, 50–57
Liver

chronic disease of, glycine loading test in, 860–865
function studies in fasting, 675–683
hypothalamic mechanisms of metabolism in, 300–309
metabolism in ethanol oxidation, glucose affecting, 776–780
weight and composition after trauma, 509–517
Lung cancer, adrenal cortical function in, 609–618
Luteinizing hormone
levels after dialysis in males, 1062–1066
produced by pituitary adenomas, 782–788
Lysine
in plasma, glucagon affecting, 265–275
and vasopressin test of hypothalamic-pituitary-adrenal function, 476–482

Magnesium
excretion of
diuretics affecting, 1048–1053
parathyroid hormone affecting, 63–69
glucose and insulin infusions affecting levels of, 439–443
Mannitol diuresis, electrolyte excretion in, 1048–1053
Mannoheptulose, effects of, 87–101, 422–425
Medical education, impediments in, 879–881
Menstrual cycle, growth hormone secretion in, 606–607
Mercaptomerin diuresis, electrolyte excretion in, 1048–1053
Methandrostenolone, effects in starvation, 585–591
Methionine in plasma, glucagon affecting, 265–275
Metyrapone test, in Cushing's syndrome, 175–191
Microcirculation, in lipemia retinalis, 978–985
Mineral removal from bone, 115–118
Monoamine oxidase inhibitors, affecting thyroxine uptake by brain, 800–810
Mucopolysaccharidosis, urinary amino acids in, 713–719
Muscular dystrophy, iodinated amino acids in, affecting serum creatine phosphokinase, 1–5
Myeloma, multiple, bone cell metabolism in, 38–49
Myotonia dystrophica, insulin responses in, 764–768
Nicotinic acid
affecting cholesterol and bile acid metabolism, 427–431
inhibiting lipolysis, 913
plasma FFA rebond after, adrenergic blockade affecting, 226–232
Nitrogen
balance
DH-581 affecting, 919
low calorie diet affecting, in obesity, 193–208
excretion after trauma, diet affecting, 509–517
from labeled glycine, metabolism of, 416–421
Norepinephrine
affecting thyroxine uptake by muscle, 343
coffee ingestion affecting excretion of, 2–8–291
Nucleotides, adenine, affecting thyroid hormone release, 331–336

Obese-hyperglycemic mice
insulin resistance in, 998–1005
mannoheptulose effects in, 422–425
Obesity
in adolescence, epinephrine and propranolol infusions in, 497–506
exercise in, metabolic effects of, 1013–1019
and fluid retention after cellulose ingestion, 945–960
free fatty acid turnover rate in, 18–31
genetic, plasma triglycerides in, 833–839
glucose turnover in, 570–582
growth hormone levels in
agents affecting, 986–991
and glucose tolerance test, 811–818
lipid mobilization in, 840–849
low calorie diet affecting blood constituents in, 193–208
mannoheptulose effects in, 422–425
water diet in, aldosterone and sodium excretion in, 700–705
See also Adipose tissue; Diet; Starvation
Ornithine in plasma, glucagon affecting, 265–275
Osseous system. *See* Bone
Osteolytic sterols, in tumors, 646–651
Oxygen lack, affecting amino acid levels, 1044–1061

Palmitate transport, across perfused placenta, 406–414
Pancreas
insulin release in transplantable islet-cell tumors, 433–437
serosal gut loop material affecting, 71–72
starvation affecting insulin and glucagon release from, 155–160

Pancreatitis, and renal clearance of amylase, 669–673
Papain-digested bovine growth hormone, metabolic effects of, 895–899
Paralysis, periodic, thyrotoxic hypokalemic, sarcoplasmic reticulum in, 81–83
Parathyroid hormone
  affecting excretion of solutes, 63–69
  affecting renal cortical adenyl cyclase, 968–972
Parathyroid stimulation, thiazide-induced, 867–872
Peptides
  placental, 593–597
  urinary, diabetogenic. *See* Diabetes, lipoatrophic
Peptiduria, glycylproline, in familial hyperostosis, 692–698
Phenformin
  inhibiting lipolysis, 926–929
  in nondiabetic humans, 148–153
Phentolamine
  affecting FFA rebound after nicotinic acid, 226–232
  affecting insulin levels in pheochromocytoma, 453, 455–456
  affecting thyroid function, 961–966
Phenylalanine in plasma, glucagon affecting, 265–275
Phenylbutazone, affecting glucose absorption, 599–604
Pheochromocytoma, carbohydrate intolerance in, 445–457
Phosphatase, alkaline, levels after brain stimulation, 300–309
Phosphate
  blood levels after glucose in starvation, 754–762
  dietary supplements affecting calcium balance in immobilization, 349–366
  urinary levels, parathyroid hormone affecting, 63–69
Phosphokinase, creatine, in muscular dystrophy, iodinated amino acids affecting, 1–5
Phospholipid levels, after brain stimulation, 300–309
Phospholipogenesis, adrenergic blocking agents affecting, 964–965
Phosphorus
  blood levels of, thiazide affecting, 867–872
  in bone, vitamin D affecting, 627
Phytosterols, in tumors, 646–651
Pituitary gland
  gonadotropin excretion in XYY syndrome, 993–996
  hormone production by adenomas, 782–788
  hypothalamic-pituitary function tests, 376–385, 476–482
  insufficiency of
    with acromegaly, 469–475
    hyponatremia in, 821–831
  reserves after dexamethasone, 376–385
  serum gonadotropin levels after dialysis in males, 1062–1066
  tumor of, corticosteroid excretion in, 277–286
Placenta
  peptide hormone of, 593–597
  perfused, palmitate transport across, 406–414
Porphobilinogen excretion, in glycine loading test, 860–865
  in starvation, 901–905
Porphyria, acute intermittent, glycine loading test in, 860–865, 901
Potassium
  in bone, 33–37
  glucose and insulin infusion affecting levels of, 439–443
  hypokalemic periodic paralysis, thyrotoxic, sarcoplasmic reticulum in, 81–83
  loss of, in starvation and refeeding, 564–569
  low calorie diet affecting excretion of, in obesity, 204–205
  radioactive, in potassium metabolism studies, 663–667
Pregnancy
  and glucose production after diets and fasting, 325, 328
  palmitate transport across perfused placenta, 406–414
  placental peptide hormone, 593–597
Proline in plasma, glucagon affecting, 265–275
Propranolol
  affecting FFA rebound after nicotinic acid, 226–232
  affecting thyroid function, 961–966
  infusions in obese adolescents, 497–506
Propantheline, affecting glucose levels, 11
Propionate, inhibiting lipolysis, 913
Prostaglandin, inhibiting lipolysis, 913
Protein
  balance in starvation, anabolic steroids affecting, 585–591

dietary
and starvation ketosis, 193–208
vitamin D supplement with, 625–628
insulin affecting synthesis of, 942
loss of, in starvation and refeeding, 564–569
metabolism in adipose tissue, proteolytic digests of bovine growth hormone affecting, 895–899
thyroxine interaction with, cold affecting, 339–346
Proteinuria in diabetes, and urinary diabetogenic peptide, 556–562
Proteolytic digests of bovine growth hormone, in adipose tissue, 895–899
Pyrazinamide, affecting carbohydrate and fat metabolism, 214–224
Pyridine nucleotide levels in thyroid, affected by LATS, 132–139
Pyrogen tests
of hypothalamic-pituitary-adrenal function, 476–482
and pituitary reserve after dexamethasone, 376–385
Pyruvate
inhibiting lipolysis, 913
levels in febrile infections, 789–797

Radiography, of Achilles tendon xanthoma, 882–885
Radioimmunoassay, of follicle-stimulating hormone, 234–239
Radiorespirometric studies of biopsy specimens, 1026–1032
Renin, plasma, in pheochromocytoma, 453
Respiration pattern analysis, in serine metabolism studies, 684–690
Reticulum, sarcoplasmic, in thyrotoxic hypokalemic periodic paralysis, 81–83
Retinal lipemia, 978–984

Salicylates
affecting amino acid levels, 1044–1061
affecting glucose absorption, 599–604
affecting lipolysis in isolated fat cells, 620–623
Sarcoplasmic reticulum, in thyrotoxic hypokalemic periodic paralysis, 81–83
Selenomethionine, parathyroid uptake of, 869–870, 872
Serine
excretion in storage diseases, 713–719
metabolism of, and respiration pattern analysis, 684–690
in plasma, glucagon affecting, 265–275
β-Sitosterol
absorption of, 652–661
in tumors, 646–651
Skeletal system. *See* Bone
Sodium
excretion of
diuretics affecting, 1048–1053
low calorie diet affecting, in obesity, 204–205
in water diet for obesity, 700–705
hyponatremia
assessment of, 706–711
in pituitary insufficiency, 821–831
retention of, after cellulose ingestion, 945–960
Somato-mammotropine, human chorionic, 593–597
Starvation
affecting glycerol ethers of lipids in adipose tissue, 887–893
aldosterone and sodium excretion in, 700–705
anabolic steroid preparations in, 585–591
and body composition after refeeding, 564–569
diet and fasting affecting glucose turnover, 319–329
drug metabolism in, 209–212
glycine loading in, 901–905
and hypophosphatemic response to glucose, 754–762
and insulin and glucagon release, 155–160
ketosis from, prevention of, 193–208
lipid levels in, 13–16
sulfobromophthalein retention in, 675–682
thyroid function in, adrenalectomy affecting, 311–317
See also Diet; Obesity
Steroid-stress diabetes, and early insulin response to glucose load, 248–251
Sterols
absorption of β-sitosterol, 652–661
in tumors, 646–651
See also Cholesterol
Stigmasterol, in tumors, 646–651
Storage diseases, urinary amino acids in, 713–719
Sulfisoxazole metabolism, in obesity and azotemia, 209–212
Sulfobromophthalein retention, in fasting, 675–682

Taurine, affecting cholesterol and bile acid metabolism, 427–431
Testosterone
affecting growth hormone secretion, 817

blood levels
after dialysis in males, 1062–1066
in XYY syndrome, 996
Theophylline, lipolytic response to, 926–929
β-hydroxybutyrate affecting, 906–913
salicylate affecting, 620–623
Thiamine pyrophosphate deficiency, in febrile infections, 789–797
Thiazide-induced parathyroid stimulation, 867–872
Threonine
excretion in storage diseases, 713–719
in plasma, glucagon affecting, 265–275
Thyroid function
adrenalectomy affecting, in starvation, 311–317
adrenergic blocking agents affecting, 961–966
after antithyroid drugs, 58–62
in juvenile hypothyroidism and sporadic cretinism, 488–495
in type III hyperlipoproteinemia, 52–53
Thyroid-stimulating hormone. *See* Thyrotropin
Thyroid stimulator, long-acting (LATS)
cell membrane as site of action, 720–728
compared with thyrotropin, 132–139
Thyrotoxic hypokalemic periodic paralysis, sarcoplasmic reticulum in, 81–83
Thyrotropin (TSH)
adenine nucleotides affecting, 331–336
affecting thyroxine uptake by muscle, 342
cell membrane as site of action, 720–728
compared with long-acting thyroid stimulator, 132–139
lipolytic response to, β-hydroxybutyrate affecting, 910
produced by pituitary adenomas, 782–788
Thyroxine
centrophenoxine hydrochloride affecting metabolism of, 800–810
clofibrate affecting levels of, 141–146
protein interaction with, cold affecting, 339–346
Tolbutamide
growth hormone responses to, testosterone affecting, 817
inhibiting lipolysis, 926–929
insulin responses to, in myotonia dystrophica, 764–768
responses to, in obesity, 754–762
Transketolase, erythrocyte, in thiamine deficiency, 789–797
Trauma, body composition after, diet affecting, 509–517
Triglyceride levels
after brain stimulation, 300–309
DH-581 affecting, 916–925
ethyl-p-chlorophenoxyisobutyrate affecting, 73–79
free fatty acids incorporated into, in obesity, 18–31
in genetically obese rats, 833–839
Triglyceride lipase, sodium salicylate affecting, 620–623
Triiodothyronine, affecting growth hormone in obesity, 986–991
Tryptic digests of bovine growth hormone, metabolic effects of, 895–899
Tubular acidosis, secondary, 252–263
Tumors
adrenal cortical function in lung cancer, 609–650
carbohydrate intolerance in pheochromocytoma, 445–457
hormone production by pituitary adenomas, 782–788
islet-cell, transplantable, 433–437
sterols in, 646–651
Tyrocine in plasma, glucagon affecting, 265–275

Urea diuresis, excretion of electrolytes in, 1048–1053
Uremia
acidosis in, compared with tubular acidosis, 252–263
dialysis in. *See* Dialysis
glucose and insulin infusions in, affecting magnesium and potassium levels, 439–443
lack of insulin antagonist in, 387–393
Uric acid
excretion of
in gout, ammonium chloride affecting, 519–543
parathyroid hormone affecting, 63–69
plasma levels
clofibrate affecting, 635–644
DH-581 affecting, 922, 924
low calorie diet affecting, in obesity, 193–208

Valine in plasma, glucagon affecting, 265–275
Vascular disease. *See* Atherosclerosis
Vasopressin
affecting glucose levels, 241–246
dexamethasone affecting secretion of, 821–831
Vitamin D, affecting deposition of zinc in bone, 625–628

Water
as diet in obesity. *See* Starvation
excretion of, chlorpropamide affecting, 874–877
load test, in hyponatremia with pituitary insufficiency, 821–831
retention of, and cellulose ingestion, 945–960
serum levels of, and hyponatremia assessment, 706–711

Weight
loss of. *See* Diet; Obesity; Starvation
after trauma, diet affecting, 509–517

Xanthoma of Achilles tendon, radiography of, 882–885
XYY syndrome, 17-ketosteroid excretion in, 993–996

Zinc, vitamin D affecting deposition of, in bone, 625–628

Notes to Contributors

Original Communications. Manuscripts for publication, letters and all other editorial communications should be addressed to the Editor-in-Chief, at the address given on page iv. Articles are accepted for publication on the condition that they are contributed solely to this Journal. Contributors should bear in mind the nature of the Journal, i.e., articles should have a definite metabolic application, with case reports submitted only if they include controlled observations of an exceptionally revealing nature. Papers should be as brief as possible, consistent with the subject.

The original copy and one duplicate should be submitted (table and figures also to be submitted, if possible, in duplicate). Contributions should include a page giving the authors' degrees and hospital and academic affiliations and an address for mailing proofs.

Preliminary Reports. Contributors are encouraged to submit articles in a special short form to be known as a "Preliminary Report," with the understanding that if such an article is accepted it will be printed in the next available issue, regardless of the backlog of regular articles. A "Preliminary Report" can serve as a preliminary report on work just completed, or may be a final report or an observation which does not require a lengthy write-up. To qualify for the priority given a Preliminary Report the article must not exceed 1000 words including the bibliography and can have no more than one simple table or small figure. If a figure or table is included the author should cut the 1000 words allowance by an amount sufficient to allow for the space which will be taken up by the table or figure, as no Preliminary Report may take up more than two pages in the Journal. Despite the limitations on length, data to support the conclusions stated should be included to the extent necessary.

Manuscripts should be typewritten on good quality paper, one side of the page only, with double or triple spacing and liberal margins throughout. Handwritten manuscripts, single-spaced material, and excessive interlineated corrections are unacceptable. References to the literature should follow the style of the Journal and be compiled at the end of the article in numerical sequence.

Illustrations and Tables. Position of figures and tables in the text should be marked on manuscript. METABOLISM uses arabic rather than roman numbering. Figures should carry their number and the author's name on the back; figure legends should be compiled in a separate list. To ensure clear reproduction, all copy for zinc cuts, including pen drawings and charts, should be prepared with black india ink, and a black ribbon should be used for typewritten material; for halftone work, good photographic prints or the original drawings should be supplied. Graphs should be drawn on plain white or blue-lined graph paper. Tables and illustrations should be of a size easily handled, and for all illustrations the effect of possible reduction in size to fit the Journal page should be considered.

Four illustrations and a total of one and one-half printed pages of tables are allowed gratis per article, with the contributor bearing the cost in excess of these limits; excessive engravings are charged for at $10.00 each, excessive tables at about $20.00 per page. The contributor must likewise bear all costs connected with printing color plates.

Proofreading. Contributors are provided with galley proofs and are asked to proofread them for typesetting errors. Important changes in data are allowed within reason without cost, but excessive alterations and additions must be charged to the contributor.

Reprints. Reprints of articles will be furnished to contributors when ordered in advance of publication. An order form, showing cost of reprints, is sent with proofs. Individual reprints of an article can usually be obtained by writing directly to its author (see footnote on first page).